Key Takeaways
MediciNova Inc. (MNOV) announced a new study published in Cancer Research showing its lead drug, ibudilast (MN-166), can block a key pathway in brain metastasis, a condition affecting up to 30% of cancer patients.
"Brain metastasis represents one of the most urgent and challenging frontiers in oncology,” Dr. Kazuko Matsuda, Chief Medical Officer at MediciNova, said. “The publication of this work in Cancer Research provides strong mechanistic and translational rationale to pursue biomarker-driven clinical strategies.”
The preclinical study, conducted by the Spanish National Cancer Research Centre (CNIO), found that inhibiting the MIF–CD74 signaling axis with ibudilast significantly reduced the progression of brain metastases in multiple experimental models. Researchers also identified a potential liquid biopsy biomarker in cerebrospinal fluid, which could help guide treatment. The study showed that the drug could reverse pro-metastatic immune reprogramming and suppress tumor growth in the brain.
The findings open a new therapeutic avenue for treating brain metastases, which commonly arise from lung, breast, melanoma, and colorectal cancers. MediciNova, which holds patents covering MN-166 for preventing metastasis in several cancer types, plans to collaborate with the CNIO on future clinical trials for patients with solid tumors that have spread to the brain.
The research, led by Dr. Manuel Valiente, head of the CNIO Brain Metastasis group, focused on the brain's own immune cells—microglia and macrophages. The study found that cancer cells release a protein called macrophage migration inhibitory factor (MIF) that reprograms these immune cells, converting them from a protective to a pro-metastatic state. Ibudilast was shown to block this signaling pathway.
“By focusing on brain-specific immune–microenvironment interactions rather than tumor-intrinsic alterations alone, the CNIO findings open a new therapeutic avenue that may be applicable across multiple primary tumor types,” Dr. Valiente said.
Ibudilast (MN-166) is MediciNova's lead asset and is already in late-stage clinical trials for other neurological conditions, including a Phase 3 trial for amyotrophic lateral sclerosis (ALS). While the company’s stock was flat in the recent session, the new data provides a significant opportunity in the neuro-oncology market. Brain metastases remain a high unmet medical need, as patients with them have historically been excluded from many clinical trials, limiting the development of targeted treatments.
The positive preclinical results and the identification of a biomarker signature to predict response could help de-risk future clinical development. Investors will watch for the design and initiation of human trials based on these findings.
This article is for informational purposes only and does not constitute investment advice.
